These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33002071)

  • 1. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
    J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT.
    Vlachopoulos C; Terentes-Printzios D; Laurent S; Nilsson PM; Protogerou AD; Aznaouridis K; Xaplanteris P; Koutagiar I; Tomiyama H; Yamashina A; Sfikakis PP; Tousoulis D
    JAMA Netw Open; 2019 Oct; 2(10):e1912831. PubMed ID: 31596491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
    Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPRINT trial: It's not just the blood pressure!
    Berkelmans GF; Visseren FL; Jaspers NE; Spiering W; van der Graaf Y; Dorresteijn JA
    Eur J Prev Cardiol; 2017 Sep; 24(14):1482-1484. PubMed ID: 28749177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
    Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
    Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Diastolic Blood Pressure is Not Related to Risk of First Episode of Stroke in a High-Risk Population: A Secondary Analysis of SPRINT.
    Sobieraj P; Lewandowski J; Siński M; Symonides B; Gaciong Z
    J Am Heart Assoc; 2019 Feb; 8(4):e010811. PubMed ID: 30744452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.
    Aggarwal R; Mirzan H; Chiu N; Steinkamp J
    Clin Res Cardiol; 2018 Jul; 107(7):565-569. PubMed ID: 29480390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
    Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
    J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
    Oikonomou EK; Spatz ES; Suchard MA; Khera R
    Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
    Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
    Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.